Piramal Pharma stärkt zukunftsfähige Betriebsabläufe durch Emissionsreduktion von 22,6 %, Anteil erneuerbarer Energien von 41 % und null Beanstandungen im Rahmen des OAI-Verfahrens der US-Lebensmittelüberwachungs- und Arzneimittelbehörde (USFDA)

RegulatoryPositive

AI Analysis

Summary

Piramal Pharma achieved record-low Scope 1 and Scope 2 emissions with a 22.6% reduction, increased renewable energy usage to 41%, and received zero observations in an FDA OAI inspection, marking progress on its SBTi-approved decarbonization pathway.

Outcome Details

Zero observations under FDA OAI (Oral Advisory Information) procedure

Importance:3/10

Sentiment:

0.70

sustainabilityemissions reductionrenewable energyFDA complianceenvironmentaloperational excellence

Read the original article

Published by PR Newswire Biotech on August 27, 2026 11:21 AM

Read Original